Indian pharmaceutical major Cipla on Monday announced a commercial collaboration with UK-based S&D Pharma to distribute its products in the Czech Republic and Slovakia.
S&D Pharma represents global pharmaceutical companies and manages the promotion and distribution of their products in Central Europe.
A statement from Cipla said that under the collaboration, it will sell its respiratory product portfolio in both Czech Republic and Slovakia through a Cipla-owned sales force managed by its commercial head while S&D Pharma will physically distribute all products, including respiratory products.
``This portfolio is expected to increase in the next few years,’’ Cipla said.
Cipla is one of the global leaders in respiratory medicines with its range of drugs and devices sold in over 100 countries. In the near future, once the necessary regulatory and reimbursement approvals are in place, the Salmeterol-Fluticasone fixed combination will be launched in the Czech Republic and Slovakia under the name `Fullhale’.
The Cipla statement said Fullhale will be made available in two strengths – 120 doess of 25/125 mcg salmeterol/fluticasone and 120 doses of 25/250 mcg salmeterol/fluticasone.
Apart from Croatia, where the combination is already available under the name Duohal, Cipla recently launched the product in Germany where it is distributed under the name `Serroflo’ and in Sweden where the combination was launched as ` Salmeterol-Fluticasone Cipla’.
On the Bombay Stock Exchange on Monday, Cipla gained 1.09 per cent to close trade at Rs 563.4.
